Robert Sackstein

This inventor holds 19 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Cell Therapy. Top assignees: The Brigham and Women's Hospital, Inc., Velico Medical, Inc., Health Research, Inc.. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Sackstein. Retrieved from https://idiyas.com/inventor/robert-sackstein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 16)

% Patents Active = 68.4

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 1.2

ph-index = 5

Forward Citations = 48(Granted Patents)

Location History:

Sudbury, MA (US) (2006 - 2022)
Pinecrest, FL (US) (2024)

Company Filing History:

7 out of 1,429

The Brigham and Women's Hospital, Inc.

Health Research, Inc.

patents

4. 12 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

Cell Therapy

Glycan Modification

E-Selectin

L-Selectin

Hematopoietic Cells

Beta-Galactosidase

Sialidase Inhibitors

Cytokine Induction

CD44 Polypeptide

Fucosylation

Platelet Solutions

G-CSF Administration

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12090173 - Methods to improve cell therapy (2024-09-17),

2. 11939616 - Compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells with alpha(1,3)-fucosyltransferases (2024-03-26),

3. 11535831 - Compositions and methods for modifying cell surface glycans (2022-12-27),

4. 10471103 - Methods to improve cell therapy (2019-11-12),

5. 10370642 - Hematopoietic progenitor cell populations having affinity for E-selectin / L-selectin (2019-08-06),

6. 10271541 - Platelet additive solution having a beta-galactosidase inhibitor (2019-04-30),

7. 9914913 - Compositions and methods for modifying cell surface glycans (2018-03-13),

8. 9788539 - Platelet protection solution having beta-galactosidase and sialidase inhibitors (2017-10-17),

9. 9609861 - Platelet additive solution having a β-galactosidase inhibitor (2017-04-04),

10. 9523078 - Method for increasing the E-selectin binding affinity of a population of cells expressing a CD44 polypeptide (2016-12-20),

11. 8852935 - Compositions and methods for modifying cell surface glycans (2014-10-07),

12. 8765126 - Methods of treating complications and disorders associated with G-CSF administration (2014-07-01),

13. 8728810 - Methods for modifying cell surface glycans (2014-05-20),

14. 8633026 - Cytokine induction of selectin ligands on cells (2014-01-21),

15. 8084236 - Compositions and methods for modifying cell surface glycans (2011-12-27),

Title: The Innovative Contributions of Robert Sackstein in Cell Therapy

Introduction: Robert Sackstein, based in Sudbury, Massachusetts, is a notable inventor with a significant portfolio comprising 19 patents. His work primarily focuses on advanced methods to enhance cell therapy, which have the potential to revolutionize treatment protocols in various medical fields.

Latest Patents: Sackstein's latest patents showcase his commitment to improving cell therapy techniques. One patent details methods of treatment that involve administering a population of modified cells to enforce the expression of an E-selectin and/or L-selectin ligand. These modified cells achieve a viability of at least 70% after treatment, indicating a significant advancement in the field. Another noteworthy patent discusses compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells through the use of alpha(1,3)-fucosyltransferases. This innovation presents methods for custom-modifying fucosylated lactosaminyl glycans on human cells, offering new avenues for therapeutic applications.

Career Highlights: Throughout his career, Sackstein has made remarkable contributions to biotechnology and medical research. His involvement with prestigious institutions has enabled him to explore diverse avenues in cell therapy and glycobiology. One of the notable organizations he has worked with is the Brigham and Women's Hospital, Inc., where he has conducted pivotal research contributing to the development of cutting-edge treatment methods.

Collaborations: Sackstein's work has been enriched through collaborations with esteemed colleagues, including Qiyong Peter Liu and Karin M Hoffmeister. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and the advancement of complex research projects.

Conclusion: Robert Sackstein stands out as a prominent figure in the realm of cell therapy innovation. With a substantial number of patents to his name and a clear focus on enhancing treatment methods, his contributions are paving the way for future advancements in medical treatments. As the field of cell therapy continues to evolve, Sackstein's work will undoubtedly play a crucial role in shaping its future.

Profile summary based on public USPTO records.